Immunohistochemical Staining of Slit2 in Primary and Metastatic Prostatic Adenocarcinoma  by Bartholow, Tanner L. et al.
Immunohistochemical
Staining of Slit2 in
Primary and Metastatic
Prostatic Adenocarcinoma1
Tanner L. Bartholow*, Michael J. Becich†,
Uma R. Chandran† and Anil V. Parwani‡
*University of Pittsburgh School of Medicine, Pittsburgh,
PA, USA; †Department of Biomedical Informatics, University
of Pittsburgh School of Medicine, Pittsburgh, PA, USA;
‡Department of Pathology, University of Pittsburgh
School of Medicine, Pittsburgh, PA, USA
Abstract
BACKGROUND: Conflicting roles for Slit2, a protein involved in mediating the processes of cell migration and
chemotactic response, have been previously described in prostate cancer. Here we use immunohistochemistry
to evaluate the expression of Slit2 in normal donor prostate (NDP), benign prostatic hyperplasia (BPH), high-grade
prostatic intraepithelial neoplasia (HGPIN), normal tissue adjacent to prostatic adenocarcinoma (NAC), primary pros-
tatic adenocarcinoma (PCa), and metastatic prostatic adenocarcinoma (Mets). METHODS: Tissue microarrays were
immunostained for Slit2. The staining intensities were quantified using automated image analysis software. The data
was statistically analyzed using one-way analysis of variance with subsequent Tukey tests for multiple comparisons or
a nonparametric equivalent. Eleven cases of NDP, 35 cases of NAC, 15 cases of BPH, 35 cases of HGPIN, 106 cases
of PCa, and 37 cases of Mets were analyzed. RESULTS: Specimens of PCa and HGPIN had the highest absolute stain-
ing for Slit2. Significant differences were seen between PCa and NDP (P < .05), PCa and NAC (P < .05), HGPIN and
NDP (P< .05), and HGPIN and NAC (P< .05). Whereas the average Mets staining was not significantly different from
NDP or NAC, several individual Mets cases featured intense staining. CONCLUSIONS: To our knowledge, this repre-
sents the first study comparing the immunohistochemical profiles of Slit2 in PCa and Mets to specimens of HGPIN,
BPH, NDP, and NAC. These findings suggest that Slit2 expression can be increased in HGPIN, PCa, andMets, making
it a potentially important biomarker for prostate cancer.
Translational Oncology (2011) 4, 314–320
Introduction
Aside from basal and squamous cell carcinomas of the skin, prostate
cancer is the most frequently occurring cancer in males, with more than
217,000 new cases estimated to have occurred in the United States
during 2010. In addition, it is the second leading cause of male cancer
mortality, responsible for an estimated 32,050 cancer deaths per year
[1]. Despite this, after the implementation of prostate-specific antigen
screening, researchers have estimated that clinically insignificant pros-
tate cancer is actually overdiagnosed at a rate of 29% for whites and
44% for blacks [2]. Consequently, many researchers and clinicians
have voiced a need for ways to discern high-risk patients in need of
aggressive treatment from those in whom the consequences of over-
treatment would outweigh the benefits [3,4].
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There is currently a limited amount of information in the literature
on biomarkers with the potential to discern the clinical behaviors of
prostate tumors [5]. Evaluating the expression of novel prostate cancer
biomarkers may yield not only candidates for improved diagnosis but
also prognosis prediction and therapy selection.
Slit2 is a secretory glycoprotein that maps to the gene locus 4p15.2
[6]. A homolog of the Drosophila protein Slit2, it exists with two other
mammalian slit proteins, Slit1 and Slit3, all of which are characterized
by four leucine-rich repeat domains at its N-terminus, a series of
epidermal growth factor–like domains, a laminin G domain, and a
cysteine-rich C-terminus [7]. As a ligand in the Slit/Robo system, Slit2
is responsible for guiding neural cell migration, where it has been dem-
onstrated to prevent inappropriate midline axonal crossing events [8,9].
Functions for Slit2 outside the central nervous system have also been
discovered. Among these functions are inhibiting leukocyte chemotaxis
and vascular smooth muscle migration [10,11]. Interestingly, another
work has also demonstrated that Slit2 is capable of attracting breast
cancer cells [12].
The discovery of Slit2 as a guidance cue across multiple tissue types
has prompted many studies to examine its potential as a biomarker for
cancer, with two contrasting roles for Slit2 having been proposed, with
some suggesting that it functions as a tumor suppressor, whereas others
propose that it plays a role in oncogenesis.
Supporting the notion that Slit2 confers antitumorigenic properties
are studies of cancer cells lines that have demonstrated Slit2 promoter
methylation in 59% of the breast, 77% of the non–small cell lung, and
55% of the small cell lung cancer cell lines examined [13]. Epigenetic
silencing of Slit2 has additionally been demonstrated in cases of acute
and chronic lymphocytic leukemia [14], glioma [15], renal cell carci-
noma [16], cervical cancer [17], and hepatocellular carcinoma [18], in
which the level of Slit2 messenger RNA (mRNA) has also been shown
to decrease with increasing metastatic potential [19].
Alternatively, evidence also exists to state that Slit2 possesses an
oncogenic function. Avci et al. [20] have reported that Slit2 and Robo1,
a Slit2 receptor, can also be upregulated in hepatocellular carcinomas
with advanced stages and poor tumor differentiation. In addition, an
increase in Slit2mRNA has also been noted in canine malignant mam-
mary tumors [21]. Schmid et al. [12] have shown through the use of
a transwell migration assay that the addition of Slit2 is capable of in-
ducing direct migration of breast cancer cells and, in an appropriate
cell line, may induce brain metastasis. Using a Boyden chamber assay,
Wang et al. [22] have demonstrated that Slit2 is capable of attracting
endothelial cells. In addition, they have also demonstrated in vitro that
Slit2 is capable of promoting angiogenic activity, increasing tubular
network formation in cancer. Moreover, in a study of pancreatic islet
tumors in mice, Yang et al. [23] intercrossed a transgenic mouse over-
expressing Slit2 with a nonmetastatic RIP-Tag2 mouse tumor model
and noted that the expression of Slit2 enhanced lymphangiogenesis
and promoted lymph node metastasis.
To date, only two studies have been conducted to examine the
expression of Slit2 in prostate cancer, both of which showed contrast-
ing results. One documented an increase in Slit2 mRNA expression
across multiple cases of prostate cancer, especially those with a hor-
mone refractory status [24]. The other demonstrated promoter hyper-
methylation of the Slit2 gene, supporting a hypothesis of reduced gene
expression [25].
To our knowledge, the immunoprofiles of Slit2 have not previously
been compared between specimens of benign prostate, primary prostate
adenocarcinoma, and metastatic prostate adenocarcinoma. Assessing
them will provide further information about the expression of Slit2
in prostate cancer, as well as help elucidate its potential as a diagnostic
or prognostic biomarker. Here, we compare the immunohistochemical
profiles in a series of 11 cases of normal donor prostate (NDP), 35 cases
of normal tissue adjacent to prostatic adenocarcinoma (NAC), 15 cases
of benign prostatic hyperplasia (BPH), 35 cases of high-grade pros-
tatic intraepithelial neoplasia (HGPIN), 106 cases of primary prostatic
adenocarcinoma (PCa), and 37 cases of metastatic prostatic adeno-
carcinoma (Mets) to examine if either a tumor suppressor or an onco-
genic function for Slit2 can be suggested.
Our findings indicate that the overall expression of Slit2 was higher
in HGPIN and PCa than in NDP and NAC (P < .05), although
not all cases of HGPIN and PCa featured high expression levels. Al-
though the overall differences between Mets and the normal tissues
were not significant, several Mets cases individually featured high Slit2
staining intensities.
Materials and Methods
Tissue Microarray Block Preparation
Tissue microarray (TMA) blocks were constructed with specimens
obtained from the Health Sciences Tissue Bank at the University of
Pittsburgh Medical Center. The tissue bank rendered the honest
broker services for this study, with all specimens obtained with in-
formed consent. Cores from each specific paraffin-embedded tissue
block were assembled into TMAs as previously described [26]. At the
selection of the cases for the construction of the initial TMAs, a pa-
thologist selected regions for sampling that maximized the type of
tissue defining the core. As such, there are no sections of “normal” tis-
sues that contain cancer. There were very minimal-to-no sections con-
taining normal glandular tissue in the other classifications. The final
TMAs consisted of 11 cases of NDP, 35 cases of NAC, 15 cases of
BPH, 35 cases of HGPIN, 106 cases of PCa, and 37 cases of Mets.
No specimens of HGPIN in this study contained diagnosed PCa. All
TMAs were initially prepared so that each case would be represented
at least in triplicate. Because of the variations in TMA processing, how-
ever, some cases were only able to be represented in duplicate. In such
instances, these cases were still included as a part of the final analysis.
Immunohistochemistry
Each TMA block was deparaffinized and then rehydrated with
incremental ethanol concentrations. Decloaker was then used for heat
induced epitope retrieval, followed by a 5-minute Tris-buffered saline
buffer rinse. A Dako autostainer was then used to stain the TMAs with
anti-Slit2 (working dilution 1:1600), a rabbit monoclonal antibody (cat-
alog no. 2864-1) from Epitomics (Burlingame, CA). Immunolabeling
was conducted using Dako Envision + Rabbit Polymer (catalog no.
K4003) from Dako (Carpinteria, CA). The slides were counterstained
with hematoxylin and coverslipped.
Scoring of Slides
All slides were scanned as digital whole slides images using ScanScope
XT (Aperio, Vista, CA). The individual tissue cores for each whole slide
image were viewed using Aperio ImageScope (Version 11.0.2.716) and
scored by applying the Positive Pixel Count Algorithm to each one. To
detect the Slit2 staining, a hue value of 0.1 and a hue width of 0.5 were
chosen for the algorithm, corresponding to the suggested range for the
detection of brown immunostaining using the software (Aperio Positive
Pixel Count Algorithm Instruction Manual ). By analyzing the average
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pixel intensity with a predetermined hue value and width, the stromal
tissue and cell nuclei that appear blue and do not feature the immuno-
stain are negated by the software and excluded from the final analysis
that determines the average staining intensity. This, in effect, controls
for the glandular to stromal tissue ratio present in the TMA cores. The
validity of using Aperio software for quantitative immunohistochemistry
has been previously documented [27,28]. The average staining intensity
was then determined by the software for each core, using a formula that
sums the intensities of weak, moderate, and strong staining pixels and
divides this value by the total number of weak, moderate, and strong
pixels. Staining intensities for the software are reported on a scale of 0
to 255, corresponding to light transmission through the specimen.There-
fore, higher staining intensities correspond to lower scores on the light
transmissibility scale. Scores in the range of 220 to 175 are classified as
weak staining, 175 to 100 as moderate staining, and 0 to 100 as strong
staining. To make staining scores more intuitive in our figures, our re-
sults are reported as the difference between no stain detection (255)
and the average staining intensity as reported by the software, so that
higher values correspond to the higher staining intensities. This value is
referred to as the “staining intensity” throughout the rest of the article.
The means for each case and, subsequently, for each tissue type were
then determined. For the specimens of adenocarcinoma, the Gleason
score and tumor stage, where available, were also reported. The clinical
TNM, as opposed to the pathologic TNM, staging classification was
used to assess the specimens. All means were reported with SEs.
One-way analysis of variance with subsequent Tukey tests for multi-
ple comparisons (α = 0.05) were used to compare the tissue types, PCa
carcinoma stages, and PCa Gleason scores. When the assumptions
were not met for the parametric analysis, Kruskal-Wallis tests, with sub-
sequent Dunn method for multiple comparisons, were used.
Photomicrographs of tissue cores were obtained using an Olympus
BX51 microscope (Olympus, Center Valley, PA) using Spot Advanced
V4.6 (Diagnostic Instruments, Inc) software. All images were taken
at 20×.
This study received exempt approval (PRO08040368) from the
University of Pittsburgh’s institutional review board. All authors have
read and approved of the final article.
Results
Patients’ Ages
Mean ages of patients with SDs for the tissue types in this study
were as follows: NDP = 32 ± 13 years, NAC = 64 ± 7 years, BPH =
67 ± 9 years, PIN = 64 ± 8 years, PCa = 65 ± 10 years, and Mets =
70 ± 10 years.
Staining Intensities
Mean staining scores for NDP, BPH, NAC, HGPIN, PCa, and
Mets were 113.39 ± 3.38, 123.37 ± 3.74, 116.82 ± 3.05, 142.42 ±
3.63, 135.36 ± 1.91, and 128.7 ± 4.89, respectively (Figure 1). A
Kruskal-Wallis test with subsequent Dunn method for multiple com-
parisons showed significant differences between HGPIN and NDP
(P < .05), HGPIN and NAC (P < .05), PCa and NDP (P < .05),
and PCa and NAC (P < .05).
None (0%) of 11 cases of NDP, 1 (2.9%) of 35 cases of NAC,
none (0%) of 15 cases of BPH, 10 (28.6%) of 35 cases of HGPIN,
19 (17.9%) of 106 cases of PCa, and 9 (24.3%) of 37 cases of Mets
had average staining scores in the highest intensity category.
When classified by tumor stage, the mean scores were 134.49 ± 3.50
(n = 39) in stage II, 133.51 ± 3.02 (n = 38) in stage 3, and 138.95 ±
3.37 (n = 29) in stage 4 (Figure 2). No significant differences were
seen between the stages (P = .51).
When classified by Gleason score, the average staining score was
128.25 ± 5.66 (n = 14) for those with a score of 6 or less, 135.43 ± 2.76
Figure 1.Mean Slit2 staining intensity by prostatic tissue type. Mean Slit2 staining score by prostatic tissue type. Significant differences
were seen between HGPIN and NDP (P < .05), HGPIN and NAC (P < .05), PCa and NDP (P < .05), and PCa and NAC (P < .05).
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(n = 53) for those with a score of 7, and 137.82 ± 2.95 (n = 39) for
those with a score of 8 or more (Figure 3). No significant differences
were seen between the Gleason score classifications (P = .30).
Staining Patterns
Representative photomicrographs of the TMA cores are shown
in Figure 4. Across the specimens of all tissue categories, Slit2 fea-
tured a diffuse and cytoplasmic staining pattern, with no nuclear or
predominant membranous staining pattern noted in the cores. Very
minimal-to-no staining for Slit2 was noted in the stromal cells, which
were predominantly blue from the hematoxylin counterstaining.
Discussion
In this study, we characterize the immunostaining patterns of Slit2
in primary and metastatic prostate adenocarcinoma. Only one case
between the NDP, BPH, and NAC groups featured average staining
for Slit2 in the highest intensity category. In contrast, 10 (28.6%) of
35 cases of HGPIN, 19 (17.9%) of 106 cases of PCa, and 9 (24.3%)
of 37 cases of Mets had staining scores in the highest intensity cate-
gory. The overall average staining was highest in the specimens of
HGPIN and PCa, with these classifications significantly different than
both NDP (P < .05) and NAC (P < .05) (Figure 1). It is therefore
interesting that despite having nine cases of Mets whose staining in-
tensities fell within the highest classification range, the average Mets
staining intensity across all cases was not significantly different from
the normal tissue groups. This may be explained by the fact that only
11 (10.4%) of 106 cases of PCa had average scores lower than 150,
whereas 7 (18.9%) of 37 cases of Mets had average scores lower than
150, which reduced the overall average score for the Mets more that of
the PCa group.
Figure 3. Mean Slit2 staining intensity by Gleason score. Mean Slit2 staining intensity by PCa Gleason score. No significant differences
were seen by this classification (P = .30), although the staining intensity trended higher with increasing Gleason score.
Figure 2. Mean Slit2 staining intensity by carcinoma stage. Mean Slit2 staining intensity by PCa carcinoma stage. No significant differ-
ences or trends were observed between the stages (P = .51).
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This phenomenon of different staining patterns for Slit2 in prostate
cancer has previously been noted by Latil et al. [24], who observed
varying levels of Slit2 mRNA expression across different prostate
tumors, with those cancers overexpressing Slit2 typically possessing
a hormone-refractory status. Whereas this provides a very plausible
mechanism to explain the differences that we observed in this study,
information about the hormone-responsive status of these specimens
was not available to include in the analysis.
Although our study concurs with that of Latil et al. [24] in showing
an increase in the expression of Slit2 in select cases of prostate cancer,
Yu et al. [25] have shown that Slit2 is epigenetically silenced in a
majority of metastatic prostate tumors, with the tumorigenic protein
EZH2 forming polycomb-repressive complexes capable of binding to
the Slit2 promoter, inhibiting its expression and hence function as
a tumor suppressor. Although this may account for its lower levels of
expression in several of the metastatic tumors, our data do not indicate
that this occurs universally because nine cases of metastatic prostate
cancer featured staining scores in the highest categories, whereas only
one case of NDP, NAC, or BPH fell within this classification. The
cases of metastasis featuring high levels of Slit2 expression in this study
included metastasis from the prostate to lymph node, bone, and liver,
indicative that more than one metastatic location can be involved in
cases of elevated Slit2 expression.
Similarly, differing results for the expression of Slit2 in cancer has been
noted across other tissue types. Although promoter hypermethylation,
and hence lower gene expression, has been observed in breast cancer tu-
mors and accompanying paired sera [29], other work has demonstrated
positive immunostaining for Slit2 in a series of 51 of 72 cases of breast
cancer, most commonly in tissue areas with high concentrations of
cancer cells [22].
It is also interesting that we did not observe a statistically signifi-
cant difference in the staining intensities by PCa stage (P = .51; Fig-
ure 2). Whereas an absolute increase in Slit2 staining was observed
with an increasing Gleason score, this difference did not reach statis-
tical significance (P = .30; Figure 3). These results stand in contrast
to a previous study of hepatocellular carcinoma, where Slit2 expres-
sion was found to correlate with advanced stage and poor tumor dif-
ferentiation [19].
In general, those positing that Slit2 may be linked to tumor sup-
pression have suggested multiple possible physiological mechanisms.
In breast cancer, it has been hypothesized that EphA2 receptor tyrosine
kinase, an angiogenic regulator that itself has previously been shown to
be expressed in tumor vasculature [30,31], represses endothelial Slit2
expression [32]. In a study of Slit2-transfected fibrosarcoma tumor
cells, increasing Slit2 expression decreased the expression of the anti-
apoptotic molecule Bcl-xl, as well as the cell cycle molecules Cdk6
and Cyclin D1 [33]. Others have suggested that Slit2 signaling de-
creases activated Cdc42, another cell cycle protein [34,35].
Those proposing an oncogenic role for Slit2 have suggested that it
may recruit vascular endothelial cells for angiogenesis within a tumor
mass, as recombinant Slit2 protein has been shown to attract endothe-
lial cells and promote tube formation [22]. Others have suggested that
Figure 4. Photomicrographs of TMA cores. Photomicrographs of TMA cores (20×): (A) NDP, (B) BPH, (C) NAC, (D) HGPIN, (E) PCA,
and (F) Mets. Note the predominantly cytoplasmic staining pattern, which is higher in intensity in the depicted specimens of HGPIN,
PCa, and Mets. Highest category staining was noted in 0 (0%) of 11 cases of NDP, 1 (2.9%) of 35 cases of NAC, 0 (0%) of 15 cases of
BPH, 10 (28.6%) of 35 cases of HGPIN, 19 (17.9%) of 106 cases of PCa, and 9 (24.3%) of 37 cases of Mets.
318 Slit2 Immunoprofiles in Prostate Cancer Bartholow et al. Translational Oncology Vol. 4, No. 5, 2011
the Slit2 may be increased because of an up-regulation in response to
cellular proinflammatory mediators, such as tumor necrosis factor and
interleukin 1β, hypoxia, or oncogene expression in cancer [22]. It has
also been hypothesized that, in some tumors, Slit2 may stimulate the
invasion of tumor cells away from the primary mass [36]. In one study
where A375 malignant melanoma cells were pretreated with heparin,
increased Slit2 was noted in the supernatant, whereas a decreased
concentration was noted in whole cell lysates, which may suggest an
interaction between Slit2 and heparin sensitive proteoglycans on can-
cer cells [22]. In addition, Slit2 has been shown to activate the phos-
phatidylinositol 3-kinase pathway [22], which has also been previously
implicated in oncogenesis [37].
Although, to our knowledge, a definitive reconciliation between
these two theories has not been reached, multiple theories for further
investigation have been proposed. In cases of metastasis, it has been
suggested that a local down-regulation of Slit2 may lead to a meta-
static process, whereas receptor sites expressing Slit2 may promote
oncogenesis [12]. Others have also observed that a change from a
chemoattractant to a chemorepellant response to a Slit protein has
been observed in mesodermal tissues [12,38], which also may warrant
further investigation. In addition, Song et al. [39] have also shown that
the same guidance cues may promote attraction or repulsion in neu-
rons in a manner dependent on cAMP activity, demonstrating that
two different functions are possible for a molecular cue depending on
its coaccompanying molecular physiology. Because Slit2 is only one
molecule in the Slit/Robo signaling pathway, its role in oncogenesis
may also be linked to the expression levels of its receptors, as evidenced
by the fact that other studies have also linked Robo1 to oncogenesis
[20,22,40].
Although all of these possibilities merit further examination, our
findings concur with Latil et al. [24] and suggest that a higher expres-
sion of Slit2 is more commonly seen in cases of HGPIN, PCa, and
Mets than in nonneoplastic tissues. Although, based on our data,
Slit2 does not seem to be able to distinguish between PCa and Mets,
it still seems to have clinical utility as an important biomarker for
prostate cancer.
Conclusions
These results provide a basis for the characterization of the staining
patterns and intensities of Slit2 in PCa and Mets in comparison to
benign prostate tissues. Slit2 immunostaining was overall signifi-
cantly higher in specimens of HGPIN and PCa than in benign
specimens. Although the overall staining was not higher in Mets
compared with benign prostates, several cases of Mets featured high
staining intensities for Slit2.
No significant differences or consistent trend was observed when
the specimens were compared by stage. Although the staining inten-
sity increased with increasing Gleason score, these differences were
also not significant. Slit2 staining was predominantly cytoplasmic
in the specimens that we examined across all tissues categories.
Although only one case between the NDP, BPH, and NAC groups
featured a staining intensity in the highest category, 10 (28.6%) of
35 specimens of HGPIN, 19 (17.9%) of 106 specimens of PCa, and
9 (24.3%) of 37 specimens of Mets had staining scores in the highest
intensity category. Although this study did not indicate that Slit2 can
differentiate between specimens of PCa and Mets, it does support
previous findings by Latil et al. [24] and suggests that Slit2 may be
an important biomarker for prostate cancer.
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